ACTRN12623000897662招募中2 期
A double-blinded randomised placebo-controlled trial of estradiol: investigating the effect on disordered eating symptoms of women with anorexia nervosa
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 16 Years 至 60 Years（—）
- 性别
- Female
入选标准
- •1.Diagnosis of AN (restrictive or binge-eating/purging subtype), in accordance with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5).
- •2.16 years or older in age.
- •3.Baseline body mass index (BMI) above 14
- •4.No initiation of therapies targeting AN within the 4 weeks prior to screening. This includes pharmacological and psychological therapies.
- •5.No increase or initiation of medications with appetite suppressing and/or weight loss effects within the 4 weeks prior to screening.
- •6.Demonstrated capacity to give informed consent
- •7.Participants who are engaged with an existing clinical treatment team for their AN at the time of enrolment and over the course of trial participation. For this purpose, engagement is defined as maintaining clinical contact, on average, at least every 4 weeks.
- •8.Consent for the research team to communicate with the participant’s clinical treatment team regarding a) their progress through the trial and b) communicate clinical deterioration and risks to allow facilitation of appropriate management, where clinically indicated.
排除标准
- •1.Inability to provide informed consent.
- •2.Hospitalisation within the 2 months prior to screening for the purpose of weight restoration or treatment of other medical instability that has a causal link to AN.
- •3.Physical parameters meeting Criteria for Medical Ward Admission as per the Alfred Health Eating Disorder – Inpatient Access and Treatment Pathways Guideline, namely:
- •a.High refeeding risk;
- •b.Vital signs as follows:
- •i.Systolic BP < 80 mmHg;
- •ii.Postural BP drop > 20 mmHg systolic, > 10 mmHg diastolic
- •iii.Heart rate < 40 or > 110;
- •iv.Temperature < 35.5oC
- •c.Blood tests within the preceding 7 days showing:
- •i.Blood glucose <3.0 mmol/L
- •ii.Serum sodium <130 mmol/L
- •iii.Serum magnesium <0.6 mmol/L
- •iv.Serum potassium <3.0 mmol/L
- •v.Serum phosphate <0.7 mmol/L
- •vi.Glomerular filtration rate < 60 ml/min (Cockroft-Gault)
- •vii.Albumin <27 g/L
- •viii.Liver enzymes ALT > 3 x upper limit of normal
- •ix.Neutrophils <1.0x109/L
- •4.Known history of breast, endometrial or ovarian cancer (individual, mother, or maternal grandmother)
- •5.Women aged 40 or over who have not had a normal mammogram in the last 24 months
- •6.Abnormal pap smear in the last 24 months
- •7.History of blood clots (e.g., deep vein thrombosis, pulmonary embolism)
- •8.Previous arterial thromboembolic disease (e.g., stroke)
- •9.Diagnosed with Type I diabetes, hyperthyroidism, Crohn’s disease or other conditions that reduce weight
- •10.Taking greater than or equal to 3 psychotropics
- •11.Other clinically significant cardiac, respiratory, renal, or endocrine conditions, or evidence of medical instability, at the discretion of the investigator
- •12.Concomitant neurological disorder or a history of a seizure disorder
- •13.Any contraindication to estrogen
- •14.Participants who are pregnant or lactating
- •15.Current substance use meeting DSM-5 criteria for severe substance use disorder
- •16.Per DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, or delusional disorder as assessed by the SCID-5 at the time of screening.
- •17.Use of any investigational procedure (e.g., clinical trial) within 30 days prior to randomisation. In case of exposure to an investigational medicinal product, investigator must ensure that it is adequately washed out prior to randomisation (at least 30 days or 5 half-lives of the investigational medicinal product, whatever is longer).
研究者
相似试验
招募中
3 期
Melatonin supplementation effect on the Induction of labour rates in first-time MothErs:The MyTIME TrialInduction of labourReproductive Health and Childbirth - Childbirth and postnatal careACTRN12623000502639Curtin University530
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakthrough paiBreakthrough PainMedDRA version: 8.1Level: PTClassification code 10064556EUCTR2005-002348-24-DKycomed Danmark ApS200
进行中（未招募）
1 期
Efficacy and safety of BI 655064 in patients with Lupus NephritisEUCTR2015-001750-15-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.160
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakthrough paiBreakthrough PainMedDRA version: 8.1Level: PTClassification code 10064556EUCTR2005-002348-24-DEycomed Danmark ApS200
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakthrough paiBreakthrough PainMedDRA version: 8.1Level: PTClassification code 10064556EUCTR2005-002348-24-FIycomed Danmark ApS200